Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Current hematologic malignancy reports - 1 Dec 2015

Guglielmelli Paola, Rotunno Giada, Pacilli Annalisa, Vannucchi Alessandro Maria

Abstract excerpt

The molecular landscape of patients with myelofibrosis (MF) includes "phenotypic driver" and "subclonal" mutations. The three driver (JAK2, MPL and CALR)-mutated genes currently represent major diagnostic criteria, unlike subclonal mutations that are not specific for the disease and occur in other myeloid neoplasms. Recent data indicate that selected mutations deserve prognostic significance allowing to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CALR gene
Share to MPL gene
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Prognosis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 26431835
DOI: 10.1007/s11899-015-0285-y

Genes

CALR
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?PMID 26431835Read ↗

Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.Semantic proximity Read ↗

Impact of molecular profiling on the management of patients with myelofibrosis.Semantic proximity Read ↗

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment AdvancementsSemantic proximity Read ↗

Prognostication in MF: from CBC to cytogenetics to molecular markers.Semantic proximity Read ↗

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.Semantic proximity Read ↗

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.Semantic proximity Read ↗

Mutation profiling of chronic myeloproliferative neoplasms: improving clinical-molecular prognostic models.Semantic proximity Read ↗

The Role and Impact of Non-driver Gene Mutations in Myelofibrosis.Semantic proximity Read ↗

The Role of New Technologies in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Prognosis of Primary Myelofibrosis in the Genomic Era.Semantic proximity Read ↗

Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.Semantic proximity Read ↗

Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.